Friday, June 30, 2017

Blood Cancer Journal - Table of Contents alert Volume 7 June 2017

If you are unable to see the message below, click here to view.
Blood Cancer Journal


Volume 7, June 2017

In this issue
Original Articles
Letters to the Editor
Sign up for e-alerts Sign up for e-alerts
Web feed



Acute lymphoblastic leukemia: a comprehensive review and 2017 update

T Terwilliger and M Abdul-Hay

Blood Cancer J 2017 7: e577; 10.1038/bcj.2017.53

Abstract | Full Text

Original Articles


Addition of cyclophosphamide and higher doses of dexamethasone do not improve outcomes of patients with AL amyloidosis treated with bortezomib

E Kastritis, M Gavriatopoulou, M Roussou, D Fotiou, D C Ziogas, M Migkou, E Eleutherakis-Papaiakovou, I Panagiotidis, N Kanellias, E Psimenou, E Papadopoulou, C Pamboucas, E Manios, H Gakiopoulou, A Ntalianis, A Tasidou, S Giannouli, E Terpos and M A Dimopoulos

Blood Cancer J 2017 7: e570; 10.1038/bcj.2017.47

Abstract | Full Text

A gene expression signature distinguishes innate response and resistance to proteasome inhibitors in multiple myeloma

A K Mitra, T Harding, U K Mukherjee, J S Jang, Y Li, R HongZheng, J Jen, P Sonneveld, S Kumar, W M Kuehl, V Rajkumar and B Van Ness

Blood Cancer J 2017 7: e581; 10.1038/bcj.2017.56

Abstract | Full Text

Changes in uninvolved immunoglobulins during induction therapy for newly diagnosed multiple myeloma

P Ravi, S Kumar, W Gonsalves, F Buadi, M Q Lacy, R S Go, A Dispenzieri, P Kapoor, J A Lust, D Dingli, Y Lin, S J Russell, N Leung, M A Gertz, R A Kyle, P L Bergsagel and S V Rajkumar

Blood Cancer J 2017 7: e569; 10.1038/bcj.2017.46

Abstract | Full Text

CD123 target validation and preclinical evaluation of ADCC activity of anti-CD123 antibody CSL362 in combination with NKs from AML patients in remission

L H Xie, M Biondo, S J Busfield, A Arruda, X Yang, G Vairo and M D Minden

Blood Cancer J 2017 7: e567; 10.1038/bcj.2017.52

Abstract | Full Text

The thrombopoietin/MPL axis is activated in the Gata1 low mouse model of myelofibrosis and is associated with a defective RPS14 signature

M Zingariello, L Sancillo, F Martelli, F Ciaffoni, M Marra, L Varricchio, R A Rana, C Zhao, J D Crispino and A R Migliaccio

Blood Cancer J 2017 7: e572; 10.1038/bcj.2017.51

Abstract | Full Text

Letters to the Editor


Systematic comparison of donor chimerism in peripheral blood and bone marrow after hematopoietic stem cell transplantation

C Bach, M Steffen, W Roesler, J Winkler, A Mackensen, K-D Stachel, M Metzler and B M Spriewald

Blood Cancer J 2017 7: e566; 10.1038/bcj.2017.42

Full Text

Evaluation of coagulopathy before and during induction chemotherapy for acute lymphoblastic leukaemia, including assessment of global clotting tests

K Burley, J Salem, T Phillips, C Reilly-Stitt, D I Marks, O Tunstall, J Moppett, A Mumford and C A Bradbury

Blood Cancer J 2017 7: e574; 10.1038/bcj.2017.54

Full Text

CD27 expression and its association with clinical outcome in children and adults with pro-B acute lymphoblastic leukemia

D Chen, N Gerasimčik, A Camponeschi, Y Tan, Q Wu, S Brynjolfsson, J Zheng, J Abrahamsson, J Nordlund, G Lönnerholm, L Fogelstrand and I-L Mårtensson

Blood Cancer J 2017 7: e575; 10.1038/bcj.2017.55

Full Text

Outcomes of newly diagnosed myeloma patients requiring dialysis: renal recovery, importance of rapid response and survival benefit

M A Dimopoulos, M Roussou, M Gavriatopoulou, D Fotiou, D C Ziogas, M Migkou, I Panagiotidis, E Eleutherakis-Papaiakovou, N Kanellias, E Psimenou, S Marinaki, D Bacharaki, D Mparmparoussi, C Matsouka, S Giannouli, E Terpos and E Kastritis

Blood Cancer J 2017 7: e571; 10.1038/bcj.2017.49

Full Text

Significance of the absolute lymphocyte/monocyte ratio as a prognostic immune biomarker in newly diagnosed multiple myeloma

T Dosani, F Covut, R Beck, J J Driscoll, M de Lima and E Malek

Blood Cancer J 2017 7: e579; 10.1038/bcj.2017.60

Full Text

Maintenance therapy with alternating azacitidine and lenalidomide in elderly fit patients with poor prognosis acute myeloid leukemia: a phase II multicentre FILO trial

M Hunault-Berger, N Maillard, C Himberlin, C Recher, A Schmidt-Tanguy, B Choufi, C Bonmati, M Carré, M-A Couturier, E Daguindau, J-P Marolleau, F Orsini-Piocelle, J Delaunay, E Tavernier, S Lissandre, M Ojeda-Uribe, L Sanhes, L Sutton, A Banos, L M Fornecker, M Bernard, D Bouscary, A Saad, M Puyade, V Rouillé, I Luquet, M C Béné, J-F Hamel, F Dreyfus, N Ifrah and A Pigneux for the FILO Group

Blood Cancer J 2017 7: e568; 10.1038/bcj.2017.50

Full Text

VEGF, VEGFR2 and GSTM1 polymorphisms in outcome of multiple myeloma patients treated with thalidomide-based regimens

L Lopes-Aguiar, M T Delamain, A B C Brito, G J Lourenço, E F D Costa, G B Oliveira, J Vassallo, C A De Souza and C S P Lima

Blood Cancer J 2017 7: e580; 10.1038/bcj.2017.58

Abstract | Full Text

Cryptic t(3;8)(q27;q24) and/or MYC-BCL6 linkage associated with MYC expression by immunohistochemistry is frequent in multiple-hit B-cell lymphomas

H Ohno, M Nakagawa, C Kishimori, K Fukutsuka and G Honjo

Blood Cancer J 2017 7: e578; 10.1038/bcj.2017.59

Full Text

Assessing the effect of obesity-related traits on multiple myeloma using a Mendelian randomisation approach

M Went, A Sud, P J Law, D C Johnson, N Weinhold, A Försti, M van Duin, J S Mitchell, B Chen, R Kuiper, O W Stephens, U Bertsch, C Campo, H Einsele, W M Gregory, M Henrion, J Hillengass, P Hoffmann, G H Jackson, O Lenive, J Nickel, M M Nöthen, M I da Silva Filho, H Thomsen, B A Walker, A Broyl, F E Davies, C Langer, M Hansson, M Kaiser, P Sonneveld, H Goldschmidt, K Hemminki, B Nilsson, G J Morgan and R S Houlston

Blood Cancer J 2017 7: e573; 10.1038/bcj.2017.48

Full Text

High rate of event-free survival at 24 months with everolimus/RCHOP for untreated diffuse large B-cell lymphoma: updated results from NCCTG N1085 (Alliance)

T E Witzig, B LaPlant, T M Habermann, E McPhail, D J Inwards, I N Micallef, J P Colgan, G S Nowakowski, S M Ansell and P B Johnston

Blood Cancer J 2017 7: e576; 10.1038/bcj.2017.57

Full Text

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your account at: (You will need to log in to be recognised as a registrant).

For further technical assistance, please contact our registration department.

For print subscription enquiries, please contact our subscription department.

For other enquiries, please contact our customer feedback department.

Springer Nature |One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA

Springer Nature's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne
San Diego - San Francisco - Washington - New York - Boston

Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW.

© 2017 Macmillan Publishers Limited, part of Springer Nature. All Rights Reserved.

Springer Nature

No comments: